Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
9
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
deals
national top stories
fda
investing
san francisco blog main
startups
new york blog main
atlas venture
decibel therapeutics
dyne therapeutics
gene therapy
hearing loss
kaleido biosciences
muscular dystrophy
myotonic dystrophy type 1
rare disease drugs
regenerative medicine
roche
san diego blog main
san francisco top stories
480 biomedical
adeno-associated virus
akouos
allosteric
arsenal medical
astellas pharma
astellas pharmaceuticals
atopic dermatitis
audentes therapeutics
autoimmune disorders
avidity biosciences
azacitidine
beta-thalassemia
What
therapeutics
9
×
medicines
developing
ipo
ago
drug
million
new
raised
treat
biotech
company
data
drugs
dyne
fda
genetic
hearing
loss
muscle
rare
regenerative
startup
years
adding
address
adds
affects
aiming
aims
allosteric
americans
analytics
approach
approval
approved
balance
based
betting
billion
Language
unset
9
×
Current search:
therapeutics
×
boston
×
unset
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
